FDA Approved: LUPRON DEPOT — Supplemental Application (AbbVie Inc.)

View source ↗

Summary

FDA approved a supplemental application for LUPRON DEPOT (leuprolide acetate) submitted by AbbVie, resulting in a labeling update via a supplemental approval.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Precocious Puberty
• Endometriosis
• Prostate Cancer
• Uterine Fibroids

Drugs mentioned

• LUPRON DEPOT (LEUPROLIDE ACETATE)

Snippet

SUPPL AP for LUPRON DEPOT (LEUPROLIDE ACETATE)